130 related articles for article (PubMed ID: 28840766)
1. Immunohistochemical and molecular imaging biomarker signature for the prediction of failure site after chemoradiation for head and neck squamous cell carcinoma.
Rasmussen GB; Håkansson KE; Vogelius IR; Rasmussen JH; Friborg JT; Fischer BM; Schumaker L; Cullen K; Therkildsen MH; Bentzen SM; Specht L
Acta Oncol; 2017 Nov; 56(11):1562-1570. PubMed ID: 28840766
[TBL] [Abstract][Full Text] [Related]
2. Predictive value of quantitative diffusion-weighted imaging and 18-F-FDG-PET in head and neck squamous cell carcinoma treated by (chemo)radiotherapy.
Martens RM; Noij DP; Koopman T; Zwezerijnen B; Heymans M; de Jong MC; Hoekstra OS; Vergeer MR; de Bree R; Leemans CR; de Graaf P; Boellaard R; Castelijns JA
Eur J Radiol; 2019 Apr; 113():39-50. PubMed ID: 30927958
[TBL] [Abstract][Full Text] [Related]
3. Nodal parameters of FDG PET/CT performed during radiotherapy for locally advanced mucosal primary head and neck squamous cell carcinoma can predict treatment outcomes: SUVmean and response rate are useful imaging biomarkers.
Lin P; Min M; Lee M; Holloway L; Forstner D; Bray V; Fowler A
Eur J Nucl Med Mol Imaging; 2017 May; 44(5):801-811. PubMed ID: 28004135
[TBL] [Abstract][Full Text] [Related]
4. Computed tomography-derived radiomic signature of head and neck squamous cell carcinoma (peri)tumoral tissue for the prediction of locoregional recurrence and distant metastasis after concurrent chemo-radiotherapy.
Keek S; Sanduleanu S; Wesseling F; de Roest R; van den Brekel M; van der Heijden M; Vens C; Giuseppina C; Licitra L; Scheckenbach K; Vergeer M; Leemans CR; Brakenhoff RH; Nauta I; Cavalieri S; Woodruff HC; Poli T; Leijenaar R; Hoebers F; Lambin P
PLoS One; 2020; 15(5):e0232639. PubMed ID: 32442178
[TBL] [Abstract][Full Text] [Related]
5. Neck dissection can be avoided after sequential chemoradiotherapy and negative post-treatment positron emission tomography-computed tomography in N2 head and neck squamous cell carcinoma.
Loo SW; Geropantas K; Beadsmoore C; Montgomery PQ; Martin WM; Roques TW
Clin Oncol (R Coll Radiol); 2011 Oct; 23(8):512-7. PubMed ID: 21501953
[TBL] [Abstract][Full Text] [Related]
6. c-Met expression is a marker of poor prognosis in patients with locally advanced head and neck squamous cell carcinoma treated with chemoradiation.
Baschnagel AM; Williams L; Hanna A; Chen PY; Krauss DJ; Pruetz BL; Akervall J; Wilson GD
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(3):701-7. PubMed ID: 24521684
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value comparison between (18)F-FLT PET/CT and (18)F-FDG PET/CT volume-based metabolic parameters in patients with head and neck cancer.
Hoshikawa H; Mori T; Yamamoto Y; Kishino T; Fukumura T; Samukawa Y; Mori N; Nishiyama Y
Clin Nucl Med; 2015 Jun; 40(6):464-8. PubMed ID: 25546204
[TBL] [Abstract][Full Text] [Related]
8. Predictive and prognostic value of CT based radiomics signature in locally advanced head and neck cancers patients treated with concurrent chemoradiotherapy or bioradiotherapy and its added value to Human Papillomavirus status.
Ou D; Blanchard P; Rosellini S; Levy A; Nguyen F; Leijenaar RTH; Garberis I; Gorphe P; Bidault F; Ferté C; Robert C; Casiraghi O; Scoazec JY; Lambin P; Temam S; Deutsch E; Tao Y
Oral Oncol; 2017 Aug; 71():150-155. PubMed ID: 28688683
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
Vermorken JB; Stöhlmacher-Williams J; Davidenko I; Licitra L; Winquist E; Villanueva C; Foa P; Rottey S; Skladowski K; Tahara M; Pai VR; Faivre S; Blajman CR; Forastiere AA; Stein BN; Oliner KS; Pan Z; Bach BA;
Lancet Oncol; 2013 Jul; 14(8):697-710. PubMed ID: 23746666
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of pretreatment 18F-FDG PET/CT parameters including visual evaluation in patients with head and neck squamous cell carcinoma.
Koyasu S; Nakamoto Y; Kikuchi M; Suzuki K; Hayashida K; Itoh K; Togashi K
AJR Am J Roentgenol; 2014 Apr; 202(4):851-8. PubMed ID: 24660716
[TBL] [Abstract][Full Text] [Related]
11. Preoperative Contrast-Enhanced CT Versus ¹⁸F-FDG PET/CT Evaluation and the Prognostic Value of Extranodal Extension for Surgical Patients with Head and Neck Squamous Cell Carcinoma.
Lee JR; Choi YJ; Roh JL; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1020-7. PubMed ID: 26122372
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of fluorine-18 fluorodeoxyglucose positron-emission tomography imaging in patients with head and neck squamous cell carcinoma.
Querellou S; Abgral R; Le Roux PY; Nowak E; Valette G; Potard G; Le Duc-Pennec A; Cavarec MB; Marianovski R; Salaün PY
Head Neck; 2012 Apr; 34(4):462-8. PubMed ID: 21604320
[TBL] [Abstract][Full Text] [Related]
13. Improving the accuracy of target volume delineation by combined use of computed tomography, magnetic resonance imaging and positron emission tomography in head and neck carcinomas.
Chauhan D; Rawat S; Sharma MK; Ahlawat P; Pal M; Gupta G; Dewan A; Gupta M; Sharma S; Dodagoudar C; Pahuja A; Mitra S; Sharma SK
J Cancer Res Ther; 2015; 11(4):746-51. PubMed ID: 26881512
[TBL] [Abstract][Full Text] [Related]
14. 18F-FDG PET/CT metabolic tumor volume and total lesion glycolysis predict outcome in oropharyngeal squamous cell carcinoma.
Lim R; Eaton A; Lee NY; Setton J; Ohri N; Rao S; Wong R; Fury M; Schöder H
J Nucl Med; 2012 Oct; 53(10):1506-13. PubMed ID: 22895812
[TBL] [Abstract][Full Text] [Related]
15. Impact of tumor control and presence of visible necrosis in head and neck cancer patients treated with radiotherapy or radiochemotherapy.
Kuhnt T; Mueller AC; Pelz T; Haensgen G; Bloching M; Koesling S; Schubert J; Dunst J
J Cancer Res Clin Oncol; 2005 Nov; 131(11):758-64. PubMed ID: 16088405
[TBL] [Abstract][Full Text] [Related]
16. Induction Chemotherapy and Sequential Concomitant Chemo-radiation in Locally Advanced Head and Neck Cancers: How Induction-phase Intensity and Treatment Breaks May Impact on Clinical Outcomes.
Franco P; Potenza I; Schena M; Riva G; Pecorari G; Garzino Demo P; Fasolis M; Moretto F; Garzaro M; Di Muzio J; Melano M; Airoldi M; Ragona R; Rampino M; Ricardi U
Anticancer Res; 2015 Nov; 35(11):6247-54. PubMed ID: 26504058
[TBL] [Abstract][Full Text] [Related]
17. Comparison of PET and CT radiomics for prediction of local tumor control in head and neck squamous cell carcinoma.
Bogowicz M; Riesterer O; Stark LS; Studer G; Unkelbach J; Guckenberger M; Tanadini-Lang S
Acta Oncol; 2017 Nov; 56(11):1531-1536. PubMed ID: 28820287
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of 18F-fludeoxyglucose uptake in 287 patients with head and neck squamous cell carcinoma.
Rasmussen JH; Vogelius IR; Fischer BM; Friborg J; Aznar MC; Persson GF; Håkansson K; Kristensen CA; Bentzen SM; Specht L
Head Neck; 2015 Sep; 37(9):1274-81. PubMed ID: 24801812
[TBL] [Abstract][Full Text] [Related]
19. Clinical utility of multimodality imaging with dynamic contrast-enhanced MRI, diffusion-weighted MRI, and 18F-FDG PET/CT for the prediction of neck control in oropharyngeal or hypopharyngeal squamous cell carcinoma treated with chemoradiation.
Ng SH; Lin CY; Chan SC; Lin YC; Yen TC; Liao CT; Chang JT; Ko SF; Wang HM; Chang CJ; Wang JJ
PLoS One; 2014; 9(12):e115933. PubMed ID: 25531391
[TBL] [Abstract][Full Text] [Related]
20. Lack of fludeoxyglucose F 18 uptake in posttreatment positron emission tomography as a significant predictor of survival after subsequent surgery in multimodality treatment for patients with locally advanced esophageal squamous cell carcinoma.
Higuchi I; Yasuda T; Yano M; Doki Y; Miyata H; Tatsumi M; Fukunaga H; Takiguchi S; Fujiwara Y; Hatazawa J; Monden M
J Thorac Cardiovasc Surg; 2008 Jul; 136(1):205-12, 212.e1-3. PubMed ID: 18603077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
